First human test: how does a fatty liver drug behave in damaged livers?
NCT ID NCT07358546
Summary
This early-stage study aims to understand how a single dose of an experimental drug called efimosfermin alfa is processed by the body and how safe it is for adults with varying degrees of liver damage caused by fatty liver disease. It will enroll 32 participants with moderate to severe liver impairment to measure drug levels in the blood and monitor for side effects. The goal is to gather basic safety and dosing information to guide future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGRialto, California, 92377, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
GSK Investigational Site
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.